- The interim analysis of open-label P- IIIb ENSEMBLE study of Ocrevus (ocrelizumab) showed 85% of patients achieved no evidence of disease activity in early-stage RRMS, low annualized relapse rate, improvement in EDSS score
- The post-hoc analysis of P-III ORATORIO study of Ocrevus vs PBO showed slow loss of brain tissue within T2 MRI lesions in PPMS @120wks.
- In a 2yrs. US claims analysis, 80% of patients with twice-yearly (6mos.) dosing of Ocrevus showed highest adherence and persistence rates vs other DMTs showed, 75% of patients persist with therapy @2yrs.
Click here to read full press release/ article | Ref: Business Wire | Image: Lassonde Entrepreneur Institute